ALS - AMYOTROPHIC LATERAL SCLEROSIS

This study tests whether a combination of two drugs (galunisertib and nerandomilast) can slow the progression of ALS in people who have high levels of a protein called GREM2. The drugs aim to reduce harmful inflammation and scarring in the brain and spinal cord. The trial will in…

This early-stage trial tests an oral drug called Kamlanoflast in 40 people with ALS. The goal is to see if it is safe, tolerable, and can reduce inflammation or slow functional decline over 24 weeks. Participants must be 18-75 years old, diagnosed with ALS within the last 3 years…

This pilot study aims to find specific markers in blood platelets that can help doctors tell the difference between ALS and other motor neuron diseases. Researchers will study 60 adults—30 with early ALS and 30 with other motor neuron diseases—using advanced lab techniques. If su…

This study tests whether a simple virtual reality guided breathing program, done at home, can reduce anxiety and improve quality of life for people with ALS. About 60 participants will use a VR headset to follow relaxation exercises. The goal is to see if this approach offers a s…

This study will test a new device that combines a brain-computer interface (BCI) with Apple Vision Pro to help people with ALS, traumatic brain injury, spinal cord injury, or stroke communicate. Up to 10 participants will use the system for 3-4 months to see how well it works and…

This observational study screens 500 people with early-stage ALS (within 24 months of weakness onset) to see if they are eligible for specific early-phase ALS trials. Participants undergo clinical tests, lab work, and biomarker analysis. The study also builds a bank of blood samp…